Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 189

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 189
---
 operates and manages its business as one reportable and operating segment. The determination of a single operating segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (the “CODM”). The CODM assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the statements of operations and comprehensive loss. The monitoring of budgeted versus actual results are used in assessing performance of the segment, and making operating decisions, allocating resources, and planning and forecasting for future periods. The measure of segment assets is reported on the balance sheets as total assets.In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses:

        Year Ended

        December 31,

        2024

        2023

        External research and development expenses:

        Clinical trials expenses
         
        $
        15,626

        $
        21,200

        Consulting and outside services

        4,707

        4,770

        Other external research and development (1)

        6,911

        12,340

        Total external research and development expenses

        27,244

        38,310

        Internal research and development expenses:

        Personnel related expenses

        13,244

        16,561

        Total research and development expenses
         
        $
        40,488

        $
        54,871

      (1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.

F-25